CERUS CORP Logo

CERUS CORP

Develops pathogen inactivation technology to reduce transfusion-transmitted infections.

CERS | US

Overview

Corporate Details

ISIN(s):
US1570851014
LEI:
Country:
United States of America
Address:
1220 CONCORD AVENUE, 94520 CONCORD

Description

Cerus Corporation is a biomedical products company dedicated to safeguarding the world's blood supply. The company develops and commercializes the INTERCEPT Blood System, a pathogen inactivation technology designed to reduce the risk of transfusion-transmitted infections. The system inactivates a broad spectrum of viruses, bacteria, parasites, and leukocytes in donated blood components. It is used for platelets and plasma, with a system for red blood cells in development. Cerus provides its technology to blood centers and hospitals, aiming to establish a new standard of care for blood safety.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-26 22:07
4
English ZIP 6.5 KB
2025-11-24 23:17 English ZIP 7.4 KB
2025-11-14 22:24 English ZIP 10.4 KB
2025-11-06 23:01
10-Q
English ZIP 2.0 MB
2025-11-06 22:03
8-K
English ZIP 218.7 KB
2025-08-25 21:25
4
English ZIP 6.4 KB
2025-08-14 22:26 English ZIP 10.4 KB
2025-08-05 23:24
S-8
English ZIP 66.1 KB
2025-08-05 22:52
10-Q
English ZIP 2.1 MB
2025-08-05 22:02
8-K
English ZIP 221.5 KB
2025-07-30 19:21 English ZIP 11.0 KB
2025-06-23 22:32
8-K
English ZIP 11.4 KB
2025-06-09 19:39
8-K
English ZIP 55.6 KB
2025-06-05 00:53
4
English ZIP 7.0 KB
2025-06-05 00:48
4
English ZIP 7.1 KB

Automate Your Workflow. Get a real-time feed of all CERUS CORP filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CERUS CORP

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CERUS CORP via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.